VYJUVEK's September 2025 Approval Tests Gene Therapy Lifecycle Norms

Krystal Biotech's beremagene geperpavec-svdt (VYJUVEK) received a supplemental approval letter dated September 12, 2025, marking the third regulatory action on this biologic since its original May 2023 licensure under STN 125774. For CMC leads and regulatory affairs teams managing post-approval commitments on gene therapy biologics, the cadence of approval letters -- May 2023, August 2023, and now September 2025 -- signals that FDA is actively engaging with lifecycle submissions on this product class, and that labeling and manufacturing controls remain live variables well beyond initial licensure.

VYJUVEK is indicated for the treatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa (DEB) carrying mutation(s) in the COL7A1 gene. As a topically applied HSV-1-based gene therapy, it occupies a regulatory category where post-approval CMC changes carry heightened scrutiny under biologics licensing frameworks. The existence of a dedicated Instruction for Use document alongside the Package Insert and Medication Guide reflects the layered labeling architecture FDA requires for complex delivery systems in this space.

The availability of demographic subgroup information -- with FDA directing reviewers to Section 1.1 of the Clinical Review Memo for notable subgroup outcome analyses -- is relevant for QA and medical affairs teams monitoring real-world use across the approved adult and pediatric population. Post-approval safety and efficacy surveillance obligations under ICH Q10 and 21 CFR Part 211 principles apply to the full indicated population, and subgroup data in the review record can inform both pharmacovigilance strategy and labeling update triggers.

Source: All regulatory details cited in this article are drawn from the FDA Vaccines, Blood and Biologics product page for VYJUVEK (STN 125774), which lists approval letters dated May 19, 2023, August 7, 2023, and September 12, 2025, along with the Summary Basis for Regulatory Action and supporting labeling documents.